MONTREAL, QUEBEC -- (MARKET WIRE) -- August 17, 2006 -- Ambrilia Biopharma Inc.(TSX: AMB), a biopharmaceutical company developing innovative therapeutics in the fields of cancer and infectious diseases, announced today the latest findings on its lead HIV protease inhibitor (PI), PPL-100. Final results of the first-in-man, single dose escalation studies confirmed PPL-100 to be safe and well tolerated with a favorable pharmacokinetic (PK) profile. Using these final clinical data, the scientists, led by Drs. George Drusano and Paul G. Ambrose, at the Institute of Clinical Pharmacodynamics (ICPD), Ordway Research Institute, Albany, NY, conducted population PK modeling and Pharmacokinetic-Pharmacodynamic (PK-PD) target attainment analyses. Modeling and simulation results predict a favorable steady-state PK profile for PPL-100, suggesting that it could be a first-line, once-daily PI without the need of ritonavir (a boosting agent) co-administration for the treatment of both PI-naive and experienced HIV/AIDS patients infected with highly resistant strains of the virus. These analyses also indicate that PPL-100 offers excellent “forgiveness” in the event of a missed dose, an important characteristic to address the non-adherence issues in HIV therapy. PPL-100 could be an asset to both physicians and patients in the fight against HIV/AIDS by potentially addressing the need for safer, more convenient and effective PIs.
